Goldman Sachs has initiated coverage on Glaukos Corp (GKOS) with a Buy rating as of September 30, 2025. The current stock price stands at $96.92. This marks the firm's first assessment of the company's investment potential based on its research and analysis of Glaukos's business and industry dynamics.
Glaukos Corp, headquartered in Aliso Viejo, California, specializes in ophthalmic medical technology and pharmaceuticals, focusing on innovative therapies for glaucoma, corneal disorders, and retinal diseases. The company employs 995 full-time staff and went public on June 25, 2015. Its product offerings include Micro-Invasive Glaucoma Surgery (MIGS) devices and procedural pharmaceuticals designed to manage intraocular pressure (IOP).
The company's market capitalization is approximately $5.5 billion, with a trailing twelve months EPS of -1.55. Upcoming earnings are expected on July 28, 2026, with an estimated EPS of -0.12 and revenue of $152.8 million. Analyst consensus indicates a Buy rating, supported by 8 Strong Buy, 11 Buy, 2 Hold, and 1 Sell ratings among 22 analysts.
This update provides insight into Glaukos's standing in the healthcare sector, particularly in the treatment of eye disorders, as analysts continue to evaluate its growth prospects and market performance.